Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Attack -- A Complete Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Claud B who wrote (25822)	7/23/2000 12:12:24 PM
From: Brad Ruffin	Read Replies (1) \| Respond to of 42787

Claude, if you don't subscribe to Carpino... that is exactly what he is pointing out.

To: Claud B who wrote (25822)	7/23/2000 12:21:42 PM
From: Casaubon	Respond to of 42787

uncanny!

To: Claud B who wrote (25822)	7/23/2000 1:47:05 PM
From: el paradisio	Respond to of 42787

Claud, maybe this will help you... Message 14092472 el

To: Claud B who wrote (25822)	7/23/2000 5:58:32 PM
From: mor2danc	Respond to of 42787

WORLD'S FIRST COMMERCIALLY AVAILABLE CANCER VACCINE! POWERLUNCH; CEO BY VIEWER REQUEST ON MONDAY... here's more... ...a few facts to consider... AVXT: the facts! (updated: 4:11 PM 07/21/2000) -The autologous cancer vaccine has 55% success ratio (compared to 22% with the current best known gold standard treatment). -Nine years of data; and all data was reported, nothing was deleted or held back. -The vaccine is virtually non toxic. -Commercialized and selling cancer vaccine to patients in Australia, and patients will travel. -Plans are in process to open up business soon in Netherlands. -Plans are in process to open up business soon in Germany. -Plans are in the works on doing business in Japan. -Launch of MVAX in New Zealand planned soon! -Very close to patent approval for the other 3 cancer fighting compounds. -Patent filings for the topoismerase inhibitor and cancer fighting anti-estrogen compounds expected. -The company is planning a move to the national market on NASDAQ this year. -M-VAX blows away the current gold standard melanoma treatment, no contest. -AVAX To Acquire All Patent Rights from the Cell and Gene Therapy Laboratory of Dr. David Klatzmann at UPMC Genopoietic to Become Wholly Owned Subsidiary of AVAX Technologies. -PIPELINE: add the great AVXT pipeline to that of Genopoietics: that should make AVXT the global leader in the personalized treatment field (13 products). 1:Cartilage repair ,2:joint repair, 3:bone marrow transplants, 4:auto immune deseases, 5:multiple sclerosis, 6:gene therapy for cancer, 7:organ transplants, 8:anticancer topoisomerase inhibitor compounds, 9:cancer fighting anti-estrogen compounds, 10:M-VAX for melonoma, 11:O-VAX for ovarian cancer, 12:L-VAX for leukemia, 13:B-VAX for breast cancer. (only a 180 million dollar MARKET CAP). and... -CEO said in interview that he expects news on patent approvals for his 2 other cancer drugs. -AVXT recently got 25 million dollars in a private placement so money is not a current issue. -Expect to hear more on M-VAX sales; expect to hear more on O-VAX , B-VAX and L-VAX. -M-Vax is in late stage trial. -O-Vax is early stage and other indications are in preclinical. -Expect to hear a few more cancer applications for our vaccine (other types of cancer). -Genopoietic deal will be finalized in a matter of a few weeks: 07/19/2000. -SMALL MARKET CAP, HUGE PIPELINE (go ahead and compare it to others!). -Dr. Jonas spoke briefly of a retro virus that Genpoietic was working on but didnt elaborate further. Hmmm. -AVAX CEO stated they are looking aggessively into the possibility of doing the vaccine for earlier stage patients too. -The company stated there has been no regulatory inquiries or compliance concerns, zero. -Start of clinical development of topoisomerase inhibitors planned for later this year. -Start of clinical development in one additional cancer indication planned this year. -Extension of MVAX to earlier stage patients in progress through low-dose arm in current MM trial. -Extension of MVAX to patients in Stage 4 MM in progress. -Patients who showed a welt at the injection site (a dth response) had an 85% survival rate. ABSOULETY ASTOUNDING! deeper info: avxtinvestors.homestead.com this wasUPDATED: 07/18/2000 ... Please BOOKMARK and PASS THIS ON, thank you. This is just the ground floor for this company; much more to come, here's the history of press releases: avax-tech.com THIS STORY HAS BEEN GRADUALLY BEEN GETTING BETTER, AND BETTER AND BETTER! I encourage you to take a look.